[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/pages/docs/Risk/index.md) >> Individual ID:PBN__Risk_8113 

# __Lack of effective treatment for newly emerging infectious diseases such as covid-19__

## Articles mentionning the risk

* [Elrayies_prophylactic_2022](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_462.md)

## Mitigations of this risk

* [Investment in research and development of antiviral drugs, vaccines, and immunity studies, and emphasis on physical spaces as a means to counter epidemics](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_9997.md)

## Name of the risk

Increased vulnerability to the spread of infectious diseases, potential for higher mortality rates

## People affected by this risk

* [General population at risk of infectious diseases](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_6740.md)

## Stakeholders who can mitigate this risk

* [Medical researchers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_685.md)
* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_0.md)
* [Public health authorities](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_124.md)

## Technologies linked to the risk

* [Biotechnology](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_2293.md)
* [Medical research and development](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_7942.md)
* [Vaccine production facilities](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_9744.md)

## This Risk belongs to this RiskGroup

* [Public health risks](https://github.com/mm80843/T3.5/blob/pages/RiskGroup/PBN__RiskGroup_3.md)

## This Risk belongs to this RiskSubgroup

* [Lack of effective medical solutions](https://github.com/mm80843/T3.5/blob/pages/RiskSubgroup/PBN__RiskSubgroup_37.md)

